NDI Notification: 5 Core Documents Your Manufacturer Must Prepare Before You File

Launching a custom supplement formulation in the United States is exciting—until your FDA NDI (New Dietary Ingredient) notification gets rejected on day one of the 75-day review window. The most common reason? Missing or inadequate documentation, not the ingredient itself.

If you’re working with a Chinese OEM/ODM manufacturer, your factory’s documentation quality is the single biggest controllable variable in your NDI success rate. This article breaks down the five core documents your manufacturer must prepare before you file.

What Is NDI Notification—and Why It Exists

Under the Dietary Supplement Health and Education Act of 1994 (DSHEA), any dietary supplement introduced to the U.S. market after October 15, 1994 must have at least one of two things:

• A “history of use” demonstrating the ingredient was marketed in the U.S. before that date, or
• A premarket NDI notification submitted to FDA at least 75 days before commercial distribution

The notification is not an approval—it’s a safety review. FDA examines your documentation and can issue an objection if the evidence is insufficient. Many Chinese manufacturers simply don’t know what the FDA expects. That’s where the right OEM partner makes the difference.

The 5 Core Documents Your Manufacturer Must Prepare

1. Identity and Characterization Specification

FDA’s first question is always: What exactly is this ingredient? Your manufacturer must provide a complete identity package including:

• Chemical name, CAS number, and molecular formula
• Manufacturing process flow (source material, extraction/purification steps, any solvents used)
• Specifications for identity, purity, potency, and impurities
• Batch analysis data from at least three representative production runs

For botanical ingredients, this includes botanical authentication (macroscopic, microscopic, DNA barcoding for high-risk species), marker compound identification, and absence of adulterants. For synthesized ingredients, it includes starting material controls and reaction pathway documentation.

2. History of Use Evidence

If your ingredient has a credible history of use in another country, this is your strongest safety argument. Your manufacturer should compile:

• Sales records, import declarations, or regulatory approvals from recognized markets (EU, Canada, Australia, Japan)
• Published literature on traditional use with at least 30 years of documented use in a food or supplement context
• Evidence that the ingredient was used in the same or substantially similar form and condition as intended in your product

Critical note: FDA scrutinizes “conditions of use.” An ingredient used in Traditional Chinese Medicine decoctions is not automatically equivalent to that same extract in a capsule supplement. Your manufacturer must address this distinction explicitly.

3. Manufacturing Process and Safety Assessment Documentation

FDA needs to understand how the ingredient is made—and whether the process introduces new safety concerns. Your manufacturer should provide:

• Full description of manufacturing process with process flow diagram
• Identification of any processing agents, solvents, catalysts, or residual reagents
• Specifications for and data on residual solvents, heavy metals, microbial limits, and pesticides
• Any available toxicology data or published studies on the manufacturing by-products

If the ingredient is produced via fermentation, enzyme-catalyzed synthesis, or novel extraction methods, additional characterization data is required to demonstrate that the process does not create new hazardous substances.

4. Safety Data: Your Evidence Dossier

This is the heart of any NDI notification. FDA typically expects a weight-of-evidence safety package that may include:

• Published human clinical studies demonstrating safety at the proposed intake level
• Toxicological studies (acute toxicity, subchronic toxicity, genotoxicity) for ingredients without a strong history of use
• Published literature reviews synthesizing the available safety data
• Expert safety assessments from qualified toxicologists or regulatory consultants

Your manufacturer does not need to commission new animal or human studies—but they must be able to source and organize the existing literature in a way that tells a coherent safety story. A well-organized literature dossier is often more persuasive than raw data presented without context.

5. Stability Data and Intended Conditions of Use

FDA evaluates safety in the context of how the product will actually be used. Your manufacturer must provide:

• Stability study data demonstrating that the active ingredient remains within specification throughout the proposed shelf life
• Specification for storage conditions (temperature, humidity, light protection)
• Proposed serving size, daily intake level, and target population (adults, children, pregnant women, etc.)
• Any known contraindications, interactions, or population-specific safety concerns

If the ingredient degrades significantly under normal storage conditions, FDA will want to see data on degradation products and their safety profile.

Common NDI Rejection Reasons—and How Your OEM Partner Can Prevent Them

Based on publicly available FDA NDI correspondence, the most common rejection triggers include:

• Insufficient history of use documentation: Generic references to traditional use without specific evidence of the same form and condition
• Inadequate identity characterization: Vague descriptions of manufacturing process that prevent FDA from assessing whether the ingredient is what you claim it is
• Conditions of use mismatch: Safety data submitted for different intake levels, dosage forms, or populations than the intended product
• Undisclosed processing agents: Residual solvents or processing aids not mentioned in the notification but detected by FDA in their own analysis
• Failure to provide the actual notification: Some submitters file incomplete packages, triggering an immediate “incomplete” response that resets the 75-day clock

What to Ask Your Manufacturer Before Signing

Before you commit to an OEM partnership for an NDI-triggering formulation, ask these questions:

1. Have you prepared NDI notifications for the U.S. market before? Can you share redacted examples?
2. What is your process for identity characterization and botanical authentication?
3. Do you have a regulatory affairs team familiar with FDA DSHEA and NDI requirements?
4. Can you provide stability data in the final marketed packaging format?
5. Do you work with third-party regulatory consultants for NDI preparation and submission?

At Dongying Zuoning Bio-Tech Co., Ltd., our regulatory affairs team has experience supporting clients through the NDI notification process, including ingredient characterization, documentation package preparation, and coordination with U.S.-based regulatory consultants. We work with your compliance team to ensure the documentation package meets FDA expectations before submission.

Conclusion

The NDI notification process is demanding—but it is entirely navigable with the right documentation and the right OEM partner. Your manufacturer’s ability to produce rigorous, FDA-ready documentation is not a nice-to-have; it is the difference between a smooth 75-day review and a costly objection letter that delays your launch by months.

Spend time upfront selecting a manufacturer who understands what FDA expects. The investment in documentation quality pays for itself the first time you receive an objection letter—or the first time you don’t.

Ready to start your NDI-compliant formulation? Contact our team today.

Email: Wade@zuoningbio.com | Phone: +86 187 5469 6289 | Website: www.zuoningbio.com